Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
ecancermedicalscience 2020-May

Breast cancer and the black swan

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Bağlantı panoya kaydedilir
Michael Retsky
Romano Demicheli
William Hrushesky
Ted James
Rick Rogers
Michael Baum
Jayant Vaidya
Osaro Erhabor
Patrice Forget

Anahtar kelimeler

Öz

Most current research in cancer is attempting to find ways of preventing patients from dying after metastatic relapse. Driven by data and analysis, this project is an approach to solve the problem upstream, i.e., to prevent relapse. This project started with the unexpected observation of bimodal relapse patterns in breast and a number of other cancers. This was not explainable with the current cancer paradigm that has guided cancer therapy and early detection for many years. After much analysis using computer simulation and input from a number of medical specialties, we eventually came to the conclusion that the surgery to remove the primary tumour produced systemic inflammation for a week after surgery. This systemic inflammation apparently caused exits of cancer cells and micrometastases from dormant states and resulted in relapses in the first 3 years post-surgery. It was determined in a retrospective study that the common inexpensive perioperative non-steroidal anti-inflammatory drug (NSAID) ketorolac could curtail the early relapse events after breast cancer surgery. A second retrospective study strongly confirmed this but an apparently underpowered prospective study showed no advantage. We are analysing these data and are now proposing to test the perioperative NSAID at Beth Israel Deaconess Medical Centre with triple-negative breast cancer (TNBC) patients, the category that could respond best to the perioperative NSAID. If this works as well as we expect, we would then transfer this technology to low- and/or middle-incomes countries (LMICs), starting with Nigeria where early onset type of TNBC is common. There is an unmet need in LMICs, especially in countries like Nigeria (190 million population), for a means to prevent surgery induced relapse that we are attempting to resolve. This work aims, thus, to describe eventual mechanisms, and ways to test a solution addressing an unmet need. But first, we consider the context, including within an historical perspective, important to explain how and why a Kuhnian paradigm shift may be considered.

Keywords: bimodal relapse hazard; breast cancer; computer simulation; early relapse; mechanisms; perioperative NSAID ketorolac; proposed solution; surgery induced systemic inflammation; unmet need in Nigeria.

Facebook sayfamıza katılın

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

  • 55 dilde çalışır
  • Bilim destekli bitkisel kürler
  • Görüntüye göre bitki tanıma
  • Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
  • Aramanızla ilgili bilimsel yayınları okuyun
  • Şifalı bitkileri etkilerine göre arayın
  • İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır

Google Play badgeApp Store badge